Recent Updates
Recently added Catalysts

Ivabradine

Phase 3

Angina Pectoris | Small molecule | Other |Tango Therapeutics, Inc.|Last Updated: Mar 15, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment750
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00202566Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina PectorisPHASE3 COMPLETED 750 — — Jun 1, 2005Oct 1, 2007Mar 15, 20181 Canada
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Improvement between baseline and end of treatment of the treadmill exercise tolerance test
Secondary Endpoints
Rate pressure product
Clinical evaluation
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
Interventions
NameTypeDescription
IvabradineDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Chronic stable angina pectoris * Documented coronary artery disease * Previous treatment with atenolol or other beta-blocker agent * Exercise tolerance test positivity and stability Exclusion Criteria: * Heart rate \< 60 bpm * Congestive heart failure

Countries:Canada
Unlock Eligibility Criteria